Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease)

Journal of the American Academy of Dermatology

Volumn 48, Issue 1, 2003, Pages 55-60

  Mackay Wiggan, Julian M ^a   Cohen, David J ^a   Grossman, Marc E ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETOPOSIDE; FUROSEMIDE; ISOTRETINOIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; PROCARBAZINE; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ANASARCA; CASE REPORT; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; HEMODIALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MALE; MEDICAL LITERATURE; NEPHROGENIC FIBROSING DERMOPATHY; NONHODGKIN LYMPHOMA; PARAPROTEINEMIA; PLASMAPHERESIS; PRIORITY JOURNAL; PUVA; REVIEW; SCLEROMYXEDEMA; SKIN BIOPSY; SKIN DEFECT; SKIN DISEASE; TREATMENT OUTCOME;

EID: 0037236042     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/mjd.2003.78     Document Type: Article

References (38)

1. Cowper S, Robin H, Steinberg S, Su L, Gupta S, LeBoit P. Scleromyxedema-like cutaneous diseases in renal-dialysis patients. Lancet 2000;356:1000-1.
2. Cowper S, Su L, Bhawan J, Robin H, Leboit P. Nephrogenic fibrosing dermopathy. Am J Dermatopathol 2001;23:383-93.
3. Dubreuilh W. Fibromes miliaires folliculaires: sclerodermie consecutive. Ann Dermatol Syphil 1906;37:569-72.
4. Reitman K. Uber eine eigenartige, der sklerodermie nahestehende affection. Arch Dermatol Syphil 1908;92:417-24.
5. Montgomery H, Underwood L. Lichen myxedematosus (differentiation from cutaneous myxedemas or mucoid states). J Invest Dermatol 1953;20:213-36.
6. Gottron HA. Skleromyxödem (eine eigenartige euscheinungsform von myxothesaurodermie), Arch Dermatol Syphil 1954;199:71-91.
7. Godby A, Bergstresser P, Chaker B, Pandya A. Fatal scleromyxedema: report of a case and review of the literature. J Am Acad Dermatol 1998;38:289-94.
8. Truhan A, Roenigk H. The cutaneous mucinoses. J Am Acad Dermatol 1986;14:1-18.
9. Dinneen A, Dicken C. Scleromyxedema. J Am Acad Dermatol 1995;33:37-43.
10. Harper RA, Rispler J. Lichen myxedematosus serum stimulates human skin fibroblast proliferation. Science 1978;199:545-7.
11. Harris R, Perry H, Kyle R, Winkelman R. Treatment of scleromyxedema with melphalan. Arch Dermatol 1979;115:295-9.
12. Alligood TR, Burnett JW, Raines BL. Scleromyxedema associated with esophageal aperistalsis and dermal eosinophilia. Cutis 1981;28:60-3, 66.
13. Findlay GH. Scleromyxedema. S Afr Med J 1960;23:69-71.
14. McCarthy J, Osserman E, Lombardo P, Takatsuki K. An abnormal serum globulin in lichen myxedematosus. Arch Dermatol 1964;89:446-50.
15. Kaufman L, Gruber B, Gomez-Reino J, Miller F. Fibrogenic growth factors in the eosinophilia myalgia syndrome and the toxic oil syndrome. Arch Dermatol 1994;130:41-7.
16. Leiferman K. Cutaneous eosinophilic diseases. In: Freedberg I, Eisen A, Wolff K, Austen KF, Goldsmith L, Katz S, et al, editors. Fitzpatrick's dermatology in general medicine. 5th ed. New York: McGraw-Hill; 1999. p. 1133-4.
17. Sidransky H. Eosinophilia myalgia syndrome:a recent syndrome serving as an alert to new diseases ahead. Mod Pathol 1994;7:806-10.
18. Greenburg AS, Takagi H, Hill R, Hasan A, Murata H, Falanga V. Delayed onset of skin fibrosis after the ingestion of eosinophilia myalgia syndrome-associated L-tryptophan. J Am Acad Dermatol 1996;35:264-6.
19. Tu J, Eisen A. Scleroderma. In: Freedberg I, Eisen A, Wolff K, Austen KF, Goldsmith L, Katz S, et al, editors. Fitzpatrick's dermatology in general medicine. 5th ed. New York: McGraw-Hill; 1999. p. 2023-33.
20. Falanga V, Medsger TA Jr. Frequency levels and significance of blood eosinophilia in systemic sclerosis, localized scleroderma and eosinophilic fasciitis. J Am Acad Dermatol 1987;17:648.
21. Valeri A, Joseph R, Radhakrishnan J. A large prospective survey of anti-cardiolipin antibodies in chronic hemodialysis patients. Clin Nephrol 1999;51:116-21.
22. Fabrizi F, Sangiorgio R, Pontoriero G, Corti M, Tentori F, Troina E, et al. Antiphospholipid (aPL) antibodies in end-stage renal disease. J Nephrol 1999;12:89-94.
23. Hisler B, Boyd Savoy L, Hashimoto K. Improvement of scleromyxedema associated with isotretinoin therapy. J Am Acad Dermatol 1991;24:854-7.
24. Milam C, Cohen L, Fenske N, Ling N. Scleromyxedema:therapeutic response to isotretinoin in three patients. J Am Acad Dermatol 1988;19:469-77.
25. Brenner S, Yust I. Treatment of scleromyxedema with etretinate. J Am Acad Dermatol 1984;10:295-6.
26. Keong C, Asaka Y, Fukuro S, Miyamoto C, Katsumata M, lino Y, et al. Successful treatment of scleromyxedema with plasmapheresis and immunosuppression. J Am Acad Dermatol 1990;22:842-4.
27. Westheim A, Lookingbill D. Plasmapheresis in a patient with scleromyxedema. Arch Dermatol 1987;123:786-9.
28. D'Incan M, Franck F, Kanold J, Baun F, Achin R, Bequin AJ, et al. Scleromyxedema: complete response to extracorporeal photopheresis and steroids. Ann Dermatol Venereol 2001;128:38-41.
29. Berkson M, Lazarus G, Uberti-Benz M, Rook A. Extracorporeal photochemotherapy: a potentially useful treatment for scleromyxedema. J Am Acad Dermatol 1991;25:724.
30. Feldman P, Shapiro L, Pick A, Slatkin M. Scleromyxedema: a dramatic response to melphalan. Arch Dermatol 1969;99:51-6.
31. Chanda J. Melphalan therapy in the treatment of scleromyxedema. Arch Dermatol 1980;116:862-3.
32. Jessen R, Straight M, Becker L. Lichen myxedematosus: treatment with cyclophosphamide. Int J Dermatol 1978;17:833-9.
33. Tschen J, Chang J. Scleromyxedema: treatment with interferon alfa. J Am Acad Dermatol 1999;40:303-7.
34. Lister R, Jolles S, Whittaker S, Black C, Forgacs I, Cramp M, et al. Scleromyxedema: response to high-dose intravenous immunoglobulin (hdlVlg). J Am Acad Dermatol 2000;43:403-8.
35. Davis L, Sanal S, Sangueza O. Treatment of scleromyxedema with 2-chlorodeoxyadenosine. J Am Acad Dermatol 1996;35:288-90.
36. Bonnetblanc J, Bedane C. Regression of scleromyxedema with topical betamethasone and dimethylsulfoxide: a 30 month follow-up. Arch Dermatol 1991;127:1733-4.
37. Kaufman D, Truhan A, Roenigk H. Scleromyxedema: systemic manifestations and cosmetic improvement from dermabrasion. Cutis 1987;39:321-4.
38. Fibrosing skin condition among patients with renal disease - United States and Europe 1997-2002. MMWR/Morb Mortal Wkly Rep 2002;51:25-6.